⏳ Fetching live dividend data...
Home › Calculator › JNJ Dividend Calculator 2026
Johnson & Johnson · NYSE
Price: $230.65 · Annual div: $5.20/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in JNJ → $109.1K in 10 years · $281.81/month
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime.
Ready to invest? Open JNJ position with:
Real after-tax yield depends on where you live and how you hold JNJ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.25% | -0.55% | $225 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1.91% | -0.89% | $191 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.80% | -1.00% | $180 / yr |
| 🇬🇧 UK ISA | 0% | 2.25% | -0.55% | $225 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.05% | -0.75% | $205 / yr |
| 🇨🇦 TFSA | 0% | 2.25% | -0.55% | $225 / yr |
| 🇨🇦 CA Taxable | 25% | 1.69% | -1.11% | $169 / yr |
| 🇦🇺 Super (pension) | 15% | 1.91% | -0.89% | $191 / yr |
| 🇦🇺 AU Taxable | 30% | 1.57% | -1.22% | $158 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.66% | -1.14% | $166 / yr |
| 🇫🇷 FR Taxable | 30% | 1.57% | -1.22% | $158 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $5.20/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
JNJ pays quarterly — 4 times per year. Next ex-div: TBD.
How JNJ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for JNJ sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-04-23 | 975 | — | — | ||
| A-Award | 2026-04-23 | 975 | — | — | ||
| A-Award | 2026-04-23 | 975 | — | — | ||
| A-Award | 2026-04-23 | 1,712 | — | — | ||
| A-Award | 2026-04-23 | 1,540 | — | — | ||
| A-Award | 2026-04-23 | 975 | — | — | ||
| A-Award | 2026-04-23 | 975 | — | — | ||
| A-Award | 2026-04-23 | 975 | — | — | ||
| A-Award | 2026-04-23 | 975 | — | — | ||
| A-Award | 2026-04-23 | 975 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the JNJ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“JNJ dividend history and calculator on one page — the 62-year growth streak really hit home. I used it to explain to my son why dividend growth investing beats chasing high yields.”
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →